Social media can help physicians recruit for clinical trials, according to the findings of a study1 published in JAMA Network Open. But the study found many barriers remain for effective trial recruitment
“While social media is a promising method of communicating clinical trial information to large and diverse populations, the idea of using social media for recruitment purposes poses challenges owing to physician concerns about increased administrative burden and the risk of misinformation,” wrote Mina S. Sedrak, MD, MS, of City of Hope Duarte, Calif., and colleagues.
Researchers interviewed 44 physicians at the main academic site and 6 affiliated community sites of City of Hope in-person or by telephone for the qualitative study. All interviews were conducted between March and June 2018. An interview guide was used to explore perceptions of social media use for accrual of cancer therapeutic trials. Of the participants, 36% were women and the majority (68%) had more than 10 years of practice experience. Twenty-four of the participants were academic-based and 20 were community-based.
Data from the study was found using qualitative content analysis. Researchers found less than 5% of patients of the physicians interviewed were enrolled in clinical trials. Three themes were identified as potential advantages of social media use for trial recruitment. First, social media provides increased visibility and awareness. Second, social media improves communication, and third, social media provides a method of patient engagement. Physicians recognized that social media allowed them “to reach large populations and easily spread information about available trials”.
“Our findings revealed that physicians are not currently comfortable with or prepared to effectively use social media for cancer clinical trial recruitment,” the researchers wrote. “Although there are some aspects of these new modes of communication that physicians are enthusiastic about (ie, increased visibility and awareness), several important concerns remain.”
Among those concerns, the physicians described several disadvantages of social media, including increased administrative burden, risk of misinformation, a lack of guidance on how best to engage, and limited outreach to all available participants.
The physicians were asked for some potential strategies for more effective use of social media for trial recruitment. Among common themes discussed were increased institutional support, including resources to manage recruitment efforts on social media. Participants also suggested ways to learn the benefit of social media and training in how to effectively use social media platforms.
“Additional research is needed to further examine and better understand the risks and benefits of using social media for clinical trial recruitment, better characterize physicians’ concerns among larger cohorts, and identify methods to optimize social media use in clinical trials,” the researcher wrote. “Importantly, the use of social media for clinical recruitment has potential implications in promoting the engagement of otherwise underrepresented groups.”
Disclosures:
Sedrak, M., Sun, V., Liu, J., George, K., Wong, A., Dale, W. and Dizon, D. (2019). Physician Perceptions of the Use of Social Media for Recruitment of Patients in Cancer Clinical Trials. [online] JAMA Network Open. Available at: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2751392?widget=personalizedcontent&previousarticle=0 [Accessed 8 Oct. 2019].
Social Media Recruiting for Trials Falls Short
A survey of physicians found recruiting for trials through social media can be useful, but not for cancer therapeutic trials.
Social media can help physicians recruit for clinical trials, according to the findings of a study1 published in JAMA Network Open. But the study found many barriers remain for effective trial recruitment
“While social media is a promising method of communicating clinical trial information to large and diverse populations, the idea of using social media for recruitment purposes poses challenges owing to physician concerns about increased administrative burden and the risk of misinformation,” wrote Mina S. Sedrak, MD, MS, of City of Hope Duarte, Calif., and colleagues.
Researchers interviewed 44 physicians at the main academic site and 6 affiliated community sites of City of Hope in-person or by telephone for the qualitative study. All interviews were conducted between March and June 2018. An interview guide was used to explore perceptions of social media use for accrual of cancer therapeutic trials. Of the participants, 36% were women and the majority (68%) had more than 10 years of practice experience. Twenty-four of the participants were academic-based and 20 were community-based.
Data from the study was found using qualitative content analysis. Researchers found less than 5% of patients of the physicians interviewed were enrolled in clinical trials. Three themes were identified as potential advantages of social media use for trial recruitment. First, social media provides increased visibility and awareness. Second, social media improves communication, and third, social media provides a method of patient engagement. Physicians recognized that social media allowed them “to reach large populations and easily spread information about available trials”.
“Our findings revealed that physicians are not currently comfortable with or prepared to effectively use social media for cancer clinical trial recruitment,” the researchers wrote. “Although there are some aspects of these new modes of communication that physicians are enthusiastic about (ie, increased visibility and awareness), several important concerns remain.”
Among those concerns, the physicians described several disadvantages of social media, including increased administrative burden, risk of misinformation, a lack of guidance on how best to engage, and limited outreach to all available participants.
The physicians were asked for some potential strategies for more effective use of social media for trial recruitment. Among common themes discussed were increased institutional support, including resources to manage recruitment efforts on social media. Participants also suggested ways to learn the benefit of social media and training in how to effectively use social media platforms.
“Additional research is needed to further examine and better understand the risks and benefits of using social media for clinical trial recruitment, better characterize physicians’ concerns among larger cohorts, and identify methods to optimize social media use in clinical trials,” the researcher wrote. “Importantly, the use of social media for clinical recruitment has potential implications in promoting the engagement of otherwise underrepresented groups.”
Disclosures:
Sedrak, M., Sun, V., Liu, J., George, K., Wong, A., Dale, W. and Dizon, D. (2019). Physician Perceptions of the Use of Social Media for Recruitment of Patients in Cancer Clinical Trials. [online] JAMA Network Open. Available at: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2751392?widget=personalizedcontent&previousarticle=0 [Accessed 8 Oct. 2019].
Glecirasib Shows Promising Efficacy in KRAS G12C+ Advanced NSCLC
April 30th 2024Those who have been previously treated for KRAS G12C–mutated advanced NSCLC may benefit from treatment with glecirasib.
Applying Novel Radiotherapy Technology for Brain Tumors and Other Cancers
April 29th 2024Timothy Chen, MD, highlights how technologies such as ZAP-X and proton therapy may improve outcomes for patients with cancer.
FOLFIRI Plus ICIs Display Anti-Tumor Activity in Gastric/GEJ Cancer
April 30th 2024Using FOLFIRI as a doublet with durvalumab or a triplet with durvalumab and tremelimumab yielded positive safety in gastric/GEJ cancers.
Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery
April 22nd 2024Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.
FDA Approves Tisotumab Vedotin for Recurrent/Metastatic Cervical Cancer
April 29th 2024Tisotumab vedotin-tftv may now be given to patients with recurrent or metastatic cervical cancer, according to the FDA.
Trastuzumab-strf Gets FDA Approval in Overexpressing Breast and Gastric Cancers
April 29th 2024Patients with overexpressing breast and gastric cancers may now receive trastuzumab-strf, which has been approved by the FDA.
Glecirasib Shows Promising Efficacy in KRAS G12C+ Advanced NSCLC
April 30th 2024Those who have been previously treated for KRAS G12C–mutated advanced NSCLC may benefit from treatment with glecirasib.
Applying Novel Radiotherapy Technology for Brain Tumors and Other Cancers
April 29th 2024Timothy Chen, MD, highlights how technologies such as ZAP-X and proton therapy may improve outcomes for patients with cancer.
FOLFIRI Plus ICIs Display Anti-Tumor Activity in Gastric/GEJ Cancer
April 30th 2024Using FOLFIRI as a doublet with durvalumab or a triplet with durvalumab and tremelimumab yielded positive safety in gastric/GEJ cancers.
Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery
April 22nd 2024Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.
FDA Approves Tisotumab Vedotin for Recurrent/Metastatic Cervical Cancer
April 29th 2024Tisotumab vedotin-tftv may now be given to patients with recurrent or metastatic cervical cancer, according to the FDA.
Trastuzumab-strf Gets FDA Approval in Overexpressing Breast and Gastric Cancers
April 29th 2024Patients with overexpressing breast and gastric cancers may now receive trastuzumab-strf, which has been approved by the FDA.